Zoledronic acid for postmenopausal osteoporosis reduces fracture risk and improves BMD
The effects of intravenous zoledronic acid in Chinese women with postmenopausal osteoporosisJ Bone Miner Metab. 2011 May;29(3):328-33. doi: 10.1007/s00774-010-0223-y. Epub 2010 Oct 5
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
323 Chinese women were randomized to evaluate the efficacy and safety of a once-yearly zoledronic acid treatment for postmenopausal osteoporosis. Patients received either annual infusions of zoledronic acid or placebo for 3 consecutive years and were assessed at the end of this period. Results revealed that zoledronic acid reduced the risk of vertebral fractures and increased the bone mineral dens...
Continuing Medical Education Credits
You could be earning 0.5 CME credits for each report you read.LEARN MORE